Printer Friendly

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - New Report.

[USPRwire, Thu Jun 06 2013] Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected person's sneeze or cough, or through direct and indirect contact with nasal secretions of an infected person. The majority of RSV infections present as mild upper respiratory illnesses that often self-resolve within two weeks, but about 1% of the cases develop serious lower respiratory complications requiring hospitalization. Children under the age of two with certain health conditions are most at risk for severe RSV infections and are therefore recommended to receive RSV prophylaxis treatments. The only FDA-approved prophylactic intervention in the US is AstraZeneca's Synagis (palivizumab), a humanized monoclonal antibody against the fusion protein of the virus.

Full Report Details at



Key Questions Answered

* What are the treatment algorithms and what do most pediatricians and neonatologists adhere to?

* What unmet needs still remain and what do key opinion leaders think?

* How likely is it that Synagis' biosimilars will enter the market during the forecast period?

* What promising interventions are in the pipeline for this narrow patient segment?

* What are the likely changes in future guidelines as expected by key opinion leaders?

Key Findings

* The majority of physicians adhere to the P guidelines limiting the number of doses and narrowing the use of Synagis

* AstraZeneca, with Synagis, will continue its stronghold of the RSV market for the forecast period

* Pipeline prophylactic indications will be first in class (active/maternal immunization), and will cover complementary populations


* Overview of RSV, including epidemiology, etiology, general symptoms from infection, and US prophylaxis guidelines comparison (American Academy of Pediatrics vs National Perinatal Association).

* Annualized RSV market revenue, annual cost of therapy and utilization pattern data from 2012 and forecast for ten years to 2022.

* Key topics covered include strategic competitor assessment, market characterization, unmet needs and remaining opportunities, clinical trial overview and implications for the RSV market.

* Pipeline analysis: analysis of two pipeline vaccines and potential market and clinical position in the RSV market.

* Analysis of the current and future RSV market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Benefits

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

- EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022

- Respiratory Syncytial Virus (RSV) Prophylactic - Pipeline Assessment and Market Forecasts to 2019

- Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022

- Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2013

Copyright 2013 USPRwire

Provided by an company
COPYRIGHT 2013 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Date:Jun 6, 2013
Previous Article:MediPoint: Peripheral Vascular Stents for the Lower Extremity - Current and Future Players.
Next Article:PharmaPoint: Chronic Myeloid Leukemia (CML) - US Drug Forecast and Market Analysis to 2022.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters